Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this study was to evaluate the effects of the fast weight loss on clinic and laboratory inflammation profile, metabolic profile, reactive oxygen species (ROS) and body composition in patients with COVID and Influenza in comorbidity with NCDs.
Primary endpoints: Clinic/infectious/inflammation tests for COVID and Influenza; weight loss during 14 days. Secondary endpoints: fasting blood glucose, HbA1c, blood insulin; systolic/diastolic BP; blood lipids; ALT, AST, chest CT-scan.
Study Design. A 6-week, open, pilot prospective clinical trial with the intention-to-treat principle.
Participants: The study enrolled 72 adult people (38 women) aged from 25 to 80 years with moderate-to-severe cases COVID and Influenza in comorbidity with NCDs as T2D, hypertension, and NASH. All patients with the ARDs had in comorbidity with one or more NCDs. All patients refused for pharmacology therapy due to: either previous unsuccessful drug results; or an antimicrobial resistance profile; or drug allergy; or reluctance to take medication; or iatrogenic fear (iatrophobia); or a rich failed experience in drug treatment; and NASH.
All the patients were admitted into the out-patient department in 3-5 days after illness onset. The study was carried out in the Republic of Kazakhstan from November, 2020, through July, 2022 at University Medical Center (Astana) and ANADETO medical center.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| patients with COVID | Experimental | 27 patients with COVID in comorbidity with NCDs as T2D, hypertension, and NASH |
|
| patients with Influenza | Experimental | 35 patients with Influenza in comorbidity with NCDs as T2D, hypertension, and NASH |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| "Analimentary detoxication" (ANADETO) weight loss based on very-low-calorie-diet | Dietary Supplement | calorie restriction to 50-100 kcal/day with fat-free vegetables (tomatoes and cucumbers) with mandatory salt intake to 5-6 gr/day, hot water drinking 1000-1500 ml/day, walking at least 2,000 steps/day after normalized body temperature, and sexual self-restraint. The walking provided to promote of blood circulation and decrease in metabolic intoxication. The weight loss method lasted 14 days. Then the patients followed for 4-week a diet where they ate one meal a day without any food restriction. |
| Measure | Description | Time Frame |
|---|---|---|
| Clinic and infectious tests for COVID and Influenza | COVID was diagnosed primarily by direct detection of SARS-CoV-2 RNA by nucleic acid amplification tests with a real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay. To diagnosis of the flu was used a RT-PCR test called the Flu SC2 Multiplex Assay. | Change from Baseline at 6 Weeks |
| weight loss during 14 days | kg | Change from Baseline at 14 days |
| C-reactive protein | mg/L | Change from Baseline at 6 Weeks |
| Measure | Description | Time Frame |
|---|---|---|
| fasting blood glucose | mmol/L | Change from Baseline at 6 Weeks |
| glycosylated hemoglobin A1c | percent | Change from Baseline at 6 Weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alaty N Nabiyev, Dr. | University Medical Center | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kuat Pernekulovich Oshakbayev | Astana | 010000 | Kazakhstan |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38744929 | Derived | Oshakbayev K, Durmanova A, Zhankalova Z, Idrisov A, Bedelbayeva G, Gazaliyeva M, Nabiyev A, Tordai A, Dukenbayeva B. Weight loss treatment for COVID-19 in patients with NCDs: a pilot prospective clinical trial. Sci Rep. 2024 May 14;14(1):10979. doi: 10.1038/s41598-024-61703-1. |
Not provided
Not provided
The investigators will make data available to any investigator/reviewer on their own request, so that the personal privacy of our patients cannot be compromised.
Not provided
Not provided
Not provided
Not provided
Not provided
27 patients with COVID and 35 patients with Influenza
Not provided
Not provided
Not provided
Not provided
|
|
| blood insulin | nU/L | Change from Baseline at 6 Weeks |
| systolic/diastolic blood pressures | mmHg | Change from Baseline at 6 Weeks |
| blood lipids | mmol/L | Change from Baseline at 6 Weeks |
| alanine aminotransferase and aspartate aminotransferase | U/L | Change from Baseline at 6 Weeks |
| chest computed tomography scan | image | Change from Baseline at 14 days |
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D007251 | Influenza, Human |
| D000073296 | Noncommunicable Diseases |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D009976 | Orthomyxoviridae Infections |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided